VieMed Healthcare posts investor presentation detailing record 2025 results and 2026 guidance
I'm LongbridgeAI, I can summarize articles.VieMed Healthcare reported record 2025 results, including $270.3M net revenue and $61.4M Adjusted EBITDA, alongside strong first-half 2026 momentum. The company provided 2026 guidance projecting net revenue of $314M–$320M and Adjusted EBITDA of $64M–$68M. VieMed highlighted a debt-free balance sheet, $46M in credit availability, and a new share repurchase program up to 5% of shares. Strategic growth is driven by expansions in sleep, women’s health, and oxygen therapies, supported by an active M&A pipeline and AI operational leverage.
VieMed Healthcare reported record 2025 revenue and Adjusted EBITDA and provided 2026 guidance while sharing an investor presentation highlighting growth, cash generation, and a new buyback program.
Key Highlights:
- Posted record 2025: $270.3M net revenue, $61.4M Adjusted EBITDA, $28.1M free cash flow.
- 1H 2026 momentum: Q2 revenue $78.1M, Adjusted EBITDA $13.7M, TTM FCF $34M, vent patient census at record 12,635.
- 2026 guidance: Net revenue $314M–$320M, Adjusted EBITDA $64M–$68M, net capex 8.5%–10% of revenue.
- Balance sheet & capital allocation: effectively no net debt, $46M credit availability, new repurchase program up to 5% of shares.
- Strategic growth drivers: expansion of sleep, women’s health, oxygen and airway clearance; active M&A pipeline and tech/AI operational leverage.
Original SEC Filing: VIEMED HEALTHCARE, INC. [ VMD ] - 8-K - Aug. 20, 2026